A novel C. elegans model for identification of small molecules that target alpha-synuclein-mediated toxicity
Objective: To develop a novel transgenic C. elegans model to study dopaminergic neurodegeneration mediated by alpha-synuclein. Background: Targeting alpha-synuclein could be a disease-modifying strategy for…Exploring therapeutic viability of a non-dopaminergic target for Parkinson’s disease
Objective: Non-dopaminergic protein drug targets are of high interest to develop adjuvant treatments for currently insufficiently addressed symptoms of PD. RGS4, a regulator of G-protein…
- « Previous Page
- 1
- …
- 13
- 14
- 15